The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis.
Identifieur interne : 000092 ( Main/Exploration ); précédent : 000091; suivant : 000093The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis.
Auteurs : James J. Clark [Royaume-Uni] ; Dominic Dwyer [Royaume-Uni] ; Nina Pinwill [Royaume-Uni] ; Peter Clark [Royaume-Uni] ; Peter Johnson [Royaume-Uni] ; Allan Hackshaw [Royaume-Uni]Source :
- The Lancet. Oncology [ 1474-5488 ] ; 2021.
Descripteurs français
- KwdFr :
- MESH :
- traitement médicamenteux : Tumeurs.
- usage thérapeutique : Antinéoplasiques.
- Délai jusqu'au traitement, Enregistrements, Humains, Médecine d'État, Prise de décision clinique, Études rétrospectives.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antineoplastic Agents.
- drug therapy : Neoplasms.
- epidemiology : COVID-19.
- Clinical Decision-Making, Humans, Registries, Retrospective Studies, SARS-CoV-2, State Medicine, Time-to-Treatment.
Abstract
BACKGROUND
Cancer services worldwide had to adapt in response to the COVID-19 pandemic to minimise risk to patients and staff. We aimed to assess the national impact of COVID-19 on the prescribing of systemic anticancer treatment in England, immediately after lockdown and after the introduction of new treatments to reduce patient risk.
METHODS
We did a retrospective analysis using data from a central National Health Service England web database mandated for clinicians to register intention to start all new systemic anticancer treatments approved for use in England since 2016. We analysed the monthly number of treatment registrations in April, 2020, after the implementation of societal lockdown on March 23, 2020, and after implementation of treatment options to reduce patient risk such as oral or less immunosuppressive drugs, in May and June, 2020. We compared the number of registrations in April-June, 2020, with the mean number of registrations and SD during the previous 6 months of unaffected cancer care (September, 2019, to February, 2020). We calculated the percentage change and absolute difference in SD units for the number of registrations overall, by tumour type, and by type and line of therapy.
FINDINGS
In April, 2020, 2969 registrations were recorded, representing 1417 fewer registrations than in the control period (monthly mean 4386; 32% reduction, absolute difference 4·2 SDs, p<0·0001). In May, 2020, total registrations increased to 3950, representing a 10% reduction compared with the control period (absolute difference 1·3 SDs, p<0·0001). In June, 2020, 5022 registrations were recorded, representing a 15% increase compared with the control period (absolute difference 1·9 SDs; p<0·0001]).
INTERPRETATION
After the onset of the COVID-19 pandemic, there was a reduction in systemic anticancer treatment initiation in England. However, following introduction of treatment options to reduce patient risk, registrations began to increase in May, 2020, and reached higher numbers than the pre-pandemic mean in June, 2020, when other clinical and societal risk mitigation factors (such as telephone consultations, facemasks and physical distancing) are likely to have contributed. However, outcomes of providing less treatment or delaying treatment initiation, particularly for advanced cancers and neoadjuvant therapies, require continued assessment.
FUNDING
None.
DOI: 10.1016/S1470-2045(20)30619-7
PubMed: 33253639
PubMed Central: PMC7833889
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis.</title><author><name sortKey="Clark, James J" sort="Clark, James J" uniqKey="Clark J" first="James J" last="Clark">James J. Clark</name><affiliation wicri:level="3"><nlm:affiliation>Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK. Electronic address: james.clark12@nhs.net.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Dwyer, Dominic" sort="Dwyer, Dominic" uniqKey="Dwyer D" first="Dominic" last="Dwyer">Dominic Dwyer</name><affiliation wicri:level="3"><nlm:affiliation>Commercial Medicines Directorate, NHS England & NHS Improvement, Skipton House, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Commercial Medicines Directorate, NHS England & NHS Improvement, Skipton House, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Pinwill, Nina" sort="Pinwill, Nina" uniqKey="Pinwill N" first="Nina" last="Pinwill">Nina Pinwill</name><affiliation wicri:level="3"><nlm:affiliation>Commercial Medicines Directorate, NHS England & NHS Improvement, Skipton House, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Commercial Medicines Directorate, NHS England & NHS Improvement, Skipton House, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Clark, Peter" sort="Clark, Peter" uniqKey="Clark P" first="Peter" last="Clark">Peter Clark</name><affiliation wicri:level="3"><nlm:affiliation>Commercial Medicines Directorate, NHS England & NHS Improvement, Skipton House, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Commercial Medicines Directorate, NHS England & NHS Improvement, Skipton House, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Johnson, Peter" sort="Johnson, Peter" uniqKey="Johnson P" first="Peter" last="Johnson">Peter Johnson</name><affiliation wicri:level="1"><nlm:affiliation>Medical Directorate, NHS England & NHS Improvement, Skipton House, London, UK; Cancer Research UK Research Centre, University of Southampton, Southampton, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Medical Directorate, NHS England & NHS Improvement, Skipton House, London, UK; Cancer Research UK Research Centre, University of Southampton, Southampton</wicri:regionArea><wicri:noRegion>Southampton</wicri:noRegion></affiliation></author><author><name sortKey="Hackshaw, Allan" sort="Hackshaw, Allan" uniqKey="Hackshaw A" first="Allan" last="Hackshaw">Allan Hackshaw</name><affiliation wicri:level="4"><nlm:affiliation>Cancer Research UK and UCL Cancer Trials Centre, Cancer Institute, University College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cancer Research UK and UCL Cancer Trials Centre, Cancer Institute, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">University College de Londres</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33253639</idno><idno type="pmid">33253639</idno><idno type="doi">10.1016/S1470-2045(20)30619-7</idno><idno type="pmc">PMC7833889</idno><idno type="wicri:Area/Main/Corpus">000A19</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000A19</idno><idno type="wicri:Area/Main/Curation">000A19</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000A19</idno><idno type="wicri:Area/Main/Exploration">000A19</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis.</title><author><name sortKey="Clark, James J" sort="Clark, James J" uniqKey="Clark J" first="James J" last="Clark">James J. Clark</name><affiliation wicri:level="3"><nlm:affiliation>Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK. Electronic address: james.clark12@nhs.net.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Dwyer, Dominic" sort="Dwyer, Dominic" uniqKey="Dwyer D" first="Dominic" last="Dwyer">Dominic Dwyer</name><affiliation wicri:level="3"><nlm:affiliation>Commercial Medicines Directorate, NHS England & NHS Improvement, Skipton House, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Commercial Medicines Directorate, NHS England & NHS Improvement, Skipton House, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Pinwill, Nina" sort="Pinwill, Nina" uniqKey="Pinwill N" first="Nina" last="Pinwill">Nina Pinwill</name><affiliation wicri:level="3"><nlm:affiliation>Commercial Medicines Directorate, NHS England & NHS Improvement, Skipton House, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Commercial Medicines Directorate, NHS England & NHS Improvement, Skipton House, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Clark, Peter" sort="Clark, Peter" uniqKey="Clark P" first="Peter" last="Clark">Peter Clark</name><affiliation wicri:level="3"><nlm:affiliation>Commercial Medicines Directorate, NHS England & NHS Improvement, Skipton House, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Commercial Medicines Directorate, NHS England & NHS Improvement, Skipton House, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Johnson, Peter" sort="Johnson, Peter" uniqKey="Johnson P" first="Peter" last="Johnson">Peter Johnson</name><affiliation wicri:level="1"><nlm:affiliation>Medical Directorate, NHS England & NHS Improvement, Skipton House, London, UK; Cancer Research UK Research Centre, University of Southampton, Southampton, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Medical Directorate, NHS England & NHS Improvement, Skipton House, London, UK; Cancer Research UK Research Centre, University of Southampton, Southampton</wicri:regionArea><wicri:noRegion>Southampton</wicri:noRegion></affiliation></author><author><name sortKey="Hackshaw, Allan" sort="Hackshaw, Allan" uniqKey="Hackshaw A" first="Allan" last="Hackshaw">Allan Hackshaw</name><affiliation wicri:level="4"><nlm:affiliation>Cancer Research UK and UCL Cancer Trials Centre, Cancer Institute, University College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Cancer Research UK and UCL Cancer Trials Centre, Cancer Institute, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">University College de Londres</orgName></affiliation></author></analytic><series><title level="j">The Lancet. Oncology</title><idno type="eISSN">1474-5488</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (therapeutic use)</term><term>COVID-19 (epidemiology)</term><term>Clinical Decision-Making (MeSH)</term><term>Humans (MeSH)</term><term>Neoplasms (drug therapy)</term><term>Registries (MeSH)</term><term>Retrospective Studies (MeSH)</term><term>SARS-CoV-2 (MeSH)</term><term>State Medicine (MeSH)</term><term>Time-to-Treatment (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antinéoplasiques (usage thérapeutique)</term><term>Délai jusqu'au traitement (MeSH)</term><term>Enregistrements (MeSH)</term><term>Humains (MeSH)</term><term>Médecine d'État (MeSH)</term><term>Prise de décision clinique (MeSH)</term><term>Tumeurs (traitement médicamenteux)</term><term>Études rétrospectives (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Decision-Making</term><term>Humans</term><term>Registries</term><term>Retrospective Studies</term><term>SARS-CoV-2</term><term>State Medicine</term><term>Time-to-Treatment</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Délai jusqu'au traitement</term><term>Enregistrements</term><term>Humains</term><term>Médecine d'État</term><term>Prise de décision clinique</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Cancer services worldwide had to adapt in response to the COVID-19 pandemic to minimise risk to patients and staff. We aimed to assess the national impact of COVID-19 on the prescribing of systemic anticancer treatment in England, immediately after lockdown and after the introduction of new treatments to reduce patient risk.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>We did a retrospective analysis using data from a central National Health Service England web database mandated for clinicians to register intention to start all new systemic anticancer treatments approved for use in England since 2016. We analysed the monthly number of treatment registrations in April, 2020, after the implementation of societal lockdown on March 23, 2020, and after implementation of treatment options to reduce patient risk such as oral or less immunosuppressive drugs, in May and June, 2020. We compared the number of registrations in April-June, 2020, with the mean number of registrations and SD during the previous 6 months of unaffected cancer care (September, 2019, to February, 2020). We calculated the percentage change and absolute difference in SD units for the number of registrations overall, by tumour type, and by type and line of therapy.</p></div><div type="abstract" xml:lang="en"><p><b>FINDINGS</b></p><p>In April, 2020, 2969 registrations were recorded, representing 1417 fewer registrations than in the control period (monthly mean 4386; 32% reduction, absolute difference 4·2 SDs, p<0·0001). In May, 2020, total registrations increased to 3950, representing a 10% reduction compared with the control period (absolute difference 1·3 SDs, p<0·0001). In June, 2020, 5022 registrations were recorded, representing a 15% increase compared with the control period (absolute difference 1·9 SDs; p<0·0001]).</p></div><div type="abstract" xml:lang="en"><p><b>INTERPRETATION</b></p><p>After the onset of the COVID-19 pandemic, there was a reduction in systemic anticancer treatment initiation in England. However, following introduction of treatment options to reduce patient risk, registrations began to increase in May, 2020, and reached higher numbers than the pre-pandemic mean in June, 2020, when other clinical and societal risk mitigation factors (such as telephone consultations, facemasks and physical distancing) are likely to have contributed. However, outcomes of providing less treatment or delaying treatment initiation, particularly for advanced cancers and neoadjuvant therapies, require continued assessment.</p></div><div type="abstract" xml:lang="en"><p><b>FUNDING</b></p><p>None.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33253639</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>01</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol</ISOAbbreviation></Journal><ArticleTitle>The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis.</ArticleTitle><Pagination><MedlinePgn>66-73</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(20)30619-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(20)30619-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Cancer services worldwide had to adapt in response to the COVID-19 pandemic to minimise risk to patients and staff. We aimed to assess the national impact of COVID-19 on the prescribing of systemic anticancer treatment in England, immediately after lockdown and after the introduction of new treatments to reduce patient risk.</AbstractText><AbstractText Label="METHODS">We did a retrospective analysis using data from a central National Health Service England web database mandated for clinicians to register intention to start all new systemic anticancer treatments approved for use in England since 2016. We analysed the monthly number of treatment registrations in April, 2020, after the implementation of societal lockdown on March 23, 2020, and after implementation of treatment options to reduce patient risk such as oral or less immunosuppressive drugs, in May and June, 2020. We compared the number of registrations in April-June, 2020, with the mean number of registrations and SD during the previous 6 months of unaffected cancer care (September, 2019, to February, 2020). We calculated the percentage change and absolute difference in SD units for the number of registrations overall, by tumour type, and by type and line of therapy.</AbstractText><AbstractText Label="FINDINGS">In April, 2020, 2969 registrations were recorded, representing 1417 fewer registrations than in the control period (monthly mean 4386; 32% reduction, absolute difference 4·2 SDs, p<0·0001). In May, 2020, total registrations increased to 3950, representing a 10% reduction compared with the control period (absolute difference 1·3 SDs, p<0·0001). In June, 2020, 5022 registrations were recorded, representing a 15% increase compared with the control period (absolute difference 1·9 SDs; p<0·0001]).</AbstractText><AbstractText Label="INTERPRETATION">After the onset of the COVID-19 pandemic, there was a reduction in systemic anticancer treatment initiation in England. However, following introduction of treatment options to reduce patient risk, registrations began to increase in May, 2020, and reached higher numbers than the pre-pandemic mean in June, 2020, when other clinical and societal risk mitigation factors (such as telephone consultations, facemasks and physical distancing) are likely to have contributed. However, outcomes of providing less treatment or delaying treatment initiation, particularly for advanced cancers and neoadjuvant therapies, require continued assessment.</AbstractText><AbstractText Label="FUNDING">None.</AbstractText><CopyrightInformation>Copyright © 2021 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>James J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK. Electronic address: james.clark12@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dwyer</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Commercial Medicines Directorate, NHS England & NHS Improvement, Skipton House, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinwill</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Commercial Medicines Directorate, NHS England & NHS Improvement, Skipton House, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Commercial Medicines Directorate, NHS England & NHS Improvement, Skipton House, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Medical Directorate, NHS England & NHS Improvement, Skipton House, London, UK; Cancer Research UK Research Centre, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hackshaw</LastName><ForeName>Allan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cancer Research UK and UCL Cancer Trials Centre, Cancer Institute, University College London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Oncol. 2021 Jan;22(1):3-5</RefSource><PMID Version="1">33253642</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066491" MajorTopicYN="Y">Clinical Decision-Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013222" MajorTopicYN="N">State Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061665" MajorTopicYN="N">Time-to-Treatment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>08</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>10</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>30</Day><Hour>20</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33253639</ArticleId><ArticleId IdType="pii">S1470-2045(20)30619-7</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(20)30619-7</ArticleId><ArticleId IdType="pmc">PMC7833889</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cancer Discov. 2020 Jun;10(6):783-791</Citation><ArticleIdList><ArticleId IdType="pubmed">32345594</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Jun 20;395(10241):1919-1926</Citation><ArticleIdList><ArticleId IdType="pubmed">32473682</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2020 Sep 3;136(10):1134-1143</Citation><ArticleIdList><ArticleId IdType="pubmed">32688395</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2009 Jun;10(6):589-97</Citation><ArticleIdList><ArticleId IdType="pubmed">19482247</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2011 Jun 8;305(22):2335-42</Citation><ArticleIdList><ArticleId IdType="pubmed">21642686</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2020 Jul;21(7):904-913</Citation><ArticleIdList><ArticleId IdType="pubmed">32479787</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Discov. 2020 Aug;10(8):1121-1128</Citation><ArticleIdList><ArticleId IdType="pubmed">32398243</ArticleId></ArticleIdList></Reference><Reference><Citation>Leukemia. 2020 Jun;34(6):1637-1645</Citation><ArticleIdList><ArticleId IdType="pubmed">32332856</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2020 Jun;21(6):750-751</Citation><ArticleIdList><ArticleId IdType="pubmed">32359403</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Oct;92(10):2067-2073</Citation><ArticleIdList><ArticleId IdType="pubmed">32369209</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2020 Jul;31(7):894-901</Citation><ArticleIdList><ArticleId IdType="pubmed">32224151</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Discov. 2020 Jul 31;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32737082</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Gynecol Cancer. 2014 Sep;24(7):1326-32</Citation><ArticleIdList><ArticleId IdType="pubmed">25054445</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2020 Aug;81(2):318-356</Citation><ArticleIdList><ArticleId IdType="pubmed">32298677</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autoimmun. 2017 Dec;85:117-125</Citation><ArticleIdList><ArticleId IdType="pubmed">28728794</ArticleId></ArticleIdList></Reference><Reference><Citation>Breast Cancer Res Treat. 2016 Nov;160(1):17-28</Citation><ArticleIdList><ArticleId IdType="pubmed">27632288</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Lymphoma. 2016;57(4):872-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26325236</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2020 Jul;190(2):e64-e67</Citation><ArticleIdList><ArticleId IdType="pubmed">32420609</ArticleId></ArticleIdList></Reference><Reference><Citation>Leukemia. 2020 Sep;34(9):2354-2363</Citation><ArticleIdList><ArticleId IdType="pubmed">32647324</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Oncol. 2020 Mar;21(3):335-337</Citation><ArticleIdList><ArticleId IdType="pubmed">32066541</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 May 12;323(18):1775-1776</Citation><ArticleIdList><ArticleId IdType="pubmed">32203977</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement><orgName><li>University College de Londres</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Clark, James J" sort="Clark, James J" uniqKey="Clark J" first="James J" last="Clark">James J. Clark</name></region><name sortKey="Clark, Peter" sort="Clark, Peter" uniqKey="Clark P" first="Peter" last="Clark">Peter Clark</name><name sortKey="Dwyer, Dominic" sort="Dwyer, Dominic" uniqKey="Dwyer D" first="Dominic" last="Dwyer">Dominic Dwyer</name><name sortKey="Hackshaw, Allan" sort="Hackshaw, Allan" uniqKey="Hackshaw A" first="Allan" last="Hackshaw">Allan Hackshaw</name><name sortKey="Johnson, Peter" sort="Johnson, Peter" uniqKey="Johnson P" first="Peter" last="Johnson">Peter Johnson</name><name sortKey="Pinwill, Nina" sort="Pinwill, Nina" uniqKey="Pinwill N" first="Nina" last="Pinwill">Nina Pinwill</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/LockdownV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000092 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000092 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= LockdownV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33253639
|texte= The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33253639" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LockdownV1
| This area was generated with Dilib version V0.6.38. |  |